Well, let me try.
You can make people take more oral A2-73 to have as much as those on high dose per slide 26.
Now certain 20% to be improved. If they take more A2-73 there can be 50% of patients improvement but there is no certainty.
Nobody among us knows what exactly was going on in the trial besides low, medium and high dose cohorts. There is more to it AVXL is not releasing more info. Anecdotal evidence of dosing with DZP.
Data published at CTAD 2016 and at PK/PD is different for 57 weeks data point. In CTAD 57 weeks there is evidence of surge, in PK/KD the data seems to deny this.
The surge existence points to 90% of patients with improved scores. Lol never say 100%.
Latest data denies this. Discrepancy is due to negligence or purpose? Nobody knows.
Market Data 
Markets 
AI
